What is the SYMPHONY Study?

The SYMPHONY Study is a clinical research trial currently being conducted at select centers in the US and Canada. The study is for people with narcolepsy who are experiencing excessive daytime sleepiness (EDS) and cataplexy (sudden muscle weakness). The SYMPHONY Study is evaluating AXS-12 (reboxetine) as an investigational oral medication that may improve wakefulness and reduce occurrence of cataplexy.

What is Excessive Daytime Sleepiness (EDS)?

Excessive daytime sleepiness (EDS) is a persistent feeling of sleepiness commonly found in people with narcolepsy. EDS can affect normal sleep-wake cycles, causing people to fall asleep at unexpected times throughout the day.

What is Cataplexy?

Cataplexy is a sudden loss of muscle tone or weakness brought on by strong emotions like laughter, embarrassment, frustration, or surprise. Sometimes there may be mild weakness, such as a drooping of the eyelids. Sometimes the attack could be severe and cause a total body collapse. Cataplexy occurs in 60-70% of people with narcolepsy. While most attacks are brief, some can last several minutes.

Who Can Participate?

People who are aged 15 to 75 in the U.S. and 25 to 65 in Canada who have narcolepsy and are experiencing cataplexy. Other criteria also apply.

Why Participate?

If you’re living with narcolepsy and cataplexy, the SYMPHONY Study may be right for you.
AXS-12, or reboxetine, is being evaluated as an investigational oral medication that may
improve wakefulness and reduce occurrence of cataplexy in people living with narcolepsy. If you
are qualified to participate:

• You may receive study-related care, study medication and study evaluations at no cost.
• You may also receive compensation for your time and travel.
• You may have the opportunity to help advance potential new treatments for people with
narcolepsy.

AXS-12 is an investigational oral
medication being studied for narcolepsy with cataplexy.